Clinical trial · Observational
Early Detection of Pancreatic Cystic Neoplasms
NCT02110498CI-TRIAL-00104322completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This research is being done to learn more about pancreatic cysts. The tests that are currently available are imperfect at determining exactly what type of pancreatic cyst a person has, which cysts contain cancer, or what the risk is of developing cancer in the future. The aim of this study is to use a combination of clinical, imaging, cyst fluid analysis, and molecular markers to try to help develop better tools to answer these questions.
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cystic, Mucinous and/or Serous Neoplasm | — | UNRESOLVED | — |
| Intraductal Papillary Mucinous Neoplasm | Pancreatic Intraductal Papillary Mucinous Neoplasm | ALIAS | 0.90 |
| Pancreatic Cysts | — | UNRESOLVED | — |
| Pancreatic Mucinous-Cystic Neoplasm | Pancreatic Mucinous Cystic Neoplasm | ONTOLOGY_EXACT | 0.98 |
| Solid Pseudopapillary Tumour of the Pancreas | Solid Pseudopapillary Neoplasm of the Pancreas | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- To develop and prospectively validate a panel of molecular markers to differentiate benign pancreatic cysts from those with malignant potential using surgical pathology as the gold standard
- timeFrame
- 3 years
Secondary outcomes (1)
- measure
- To determine the sensitivity, specificity, and overall accuracy of imaging (CT, MRI and EUS) in patients with pancreatic cysts
- timeFrame
- 3 years
- description
- Sensitivity and specificity of imaging results in identifying malignant and mucinous cysts will be calculated using the pathology result as the reference gold standard. The overall accuracy of the imaging results, defined as percent agreement with pathology, will also be calculated. Estimates will be reported with exact binomial 95% confidence intervals.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Adult patients age 18 years and older with pancreatic cyst. Exclusion Criteria: * Individuals with ASA class 4 or greater. * Inability to provide informed consent. * Pregnancy or lactation.
References
Publications (0)
Data not yet available
No reference posted for this study.